Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $219.88 -1.32%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $331.00 price target on Biogen (NASDAQ: BIIB)
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $227.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen reports 52-week phase 2 data for lupus skin drug litifilimab
- DA Davidson Reiterates Buy Rating on Progress Software (PRGS) Following Q3 Print
- William Blair: 'We expect this news to add to an already burdensome (and ongoing) overhang for both EFX and TRU shares'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
